ReviewReviews in endocrine & metabolic disorders2014
Gut microbiota and GLP-1.
Review in Reviews in endocrine & metabolic disorders, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 6 syntheses or guidelines pooled it, 242 citations in OpenAlex.
- Clinical efficacy of probiotics in the treatment of diabetes kidney disease: a systematic review and meta-analysis.Frontiers in microbiology · 2025Pooled it
- A scientometric visualization analysis of the gut microbiota and gestational diabetes mellitus.Frontiers in microbiology · 2025Pooled it
- Global trends and collaborative networks in gut microbiota-insulin resistance research: a comprehensive bibliometric analysis (2000-2024).Frontiers in medicine · 2024Pooled it
- Alterations of the gut microbiota in the lupus nephritis: a systematic review.Renal failure · 2023Pooled it
- Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review.Renal failure · 2021Pooled it
- Obesity-related gut hormones and cancer: novel insight into the pathophysiology.International journal of obesity (2005) · 2021Pooled it
- Effects of Wilac D001 (Journal of microbiology and biotechnology · 2026Trial
- Trial
- Riboflavin Supplementation Promotes Butyrate Production in the Absence of Gross Compositional Changes in the Gut Microbiota.Antioxidants & redox signaling · 2023Trial
- Diets naturally rich in polyphenols and/or long-chain n-3 polyunsaturated fatty acids differently affect microbiota composition in high-cardiometabolic-risk individuals.Acta diabetologica · 2020Trial
- The Effect of White Rice and White Bread as Staple Foods on Gut Microbiota and Host Metabolism.Nutrients · 2018Trial
- Combining Short-Term Interval Training with Caloric Restriction Improves ß-Cell Function in Obese Adults.Nutrients · 2018Trial
- The Effects of Moderate Whole Grain Consumption on Fasting Glucose and Lipids, Gastrointestinal Symptoms, and Microbiota.Nutrients · 2017Trial
- Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota.Genome medicine · 2016Trial
- Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment.International journal of obesity (2005) · 2015Trial
- Effect of Non-viable Probiotics on Obesity-Related Outcomes in Rodent Models: A Systematic Review and Meta-Analysis.Probiotics and antimicrobial proteins · 2026Review
- Linkage of gut microbiota dysbiosis to chronic kidney disease in patients with graded proteinuria levels.Microbiology spectrum · 2026Article
- GLP-1 agonists and the gut microbiome: A bidirectional relationship.British journal of clinical pharmacology · 2026Review
- The Gut-Adipose-Tumor Axis in Obesity-Related Cancer.Nutrients · 2026Review
- Bile acids regulate lipid metabolism through selective actions on fatty acid absorption.Cell metabolism · 2026Article
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A large body of evidence suggests that the regulation of energy balance and glucose homeostasis by fermentable carbohydrates induces specific changes in the gut microbiota. Among the mechanisms, our research group and others have demonstrated that the gut microbiota fermentation (i.e., bacterial digestion of specific compounds) of specific prebiotics or other non-digestible carbohydrates is associated with the secretion of enteroendocrine peptides, such as the glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), produced by L-cells. In this review, we highlight past and recent results describing how dietary manipulation of the gut microbiota, using nutrients or specific microbes, can stimulate GLP-1 secretion in rodents and humans. Furthermore, the purpose of this review is to discuss the putative mechanisms by which specific bacterial metabolites, such as short chain fatty acids, trigger GLP-1 secretion through GPR41/43-dependent mechanisms. Moreover, we conclude by discussing the molecular advance showing that the endocannabinoid system or related bioactive lipids modulated by the gut microbiota may contribute to the regulation of glucose, lipid and energy homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.